-
公开(公告)号：WO2010071313A2
公开(公告)日：2010-06-24
申请号：PCT/KR2009/007212
申请日：2009-12-04
CPC classification number: A61K31/44 , A61K9/2081 , A61K9/5026 , A61K9/5078
Abstract: 본 발명은 라시디핀; 계면활성제; 및 폴리비닐피롤리돈의 혼합물이 수용성 당류의 입자 표면에 코팅되어 형성된, 라시디핀 함유 과립 및 이를 포함하는 약학 조성물에 관한 것이다. 본 발명에 따른 라시디핀 함유 과립은 수성 매질에서 우수한 용출속도 및 용해도를 나타내며, 따라서 높은 생체 이용율을 나타낼 수 있다. 특히, 본 발명에 따른 라시디핀 함유 과립으로부터 얻어진 정제 등의 고형 제제는 종래의 제제에 비하여 30 분까지의 누적 용출율을 약 2 배 이상으로 높일 수 있으므로, 신속한 약리 활성을 나타낼 뿐만 아니라 우수한 생체이용율을 나타낼 수 있다.
Abstract translation: 本发明涉及含有拉西地平的颗粒，其中将拉西地平，表面活性剂和聚乙烯吡咯烷酮的混合物涂覆在水溶性糖类颗粒的表面上，以及包含其的药物组合物。 根据本发明的含有拉西地平的颗粒在水性介质中表现出优异的溶解速率和溶解性，从而提高生物利用度。 具体地说，从本发明的含有拉西地平的颗粒得到的固体制剂如片剂等在30分钟内表现出改善的累积溶解速度，其比常规制剂快两倍，导致药理活性快和生物利用度优异。
-
公开(公告)号：KR1020140047845A
公开(公告)日：2014-04-23
申请号：KR1020120114062
申请日：2012-10-15
Applicant: 삼일제약주식회사
IPC: A61K31/4184 , A61P9/12 , A61P3/10 , A61P27/06
CPC classification number: A61K31/4184 , A61K9/167 , A61K31/549 , A61K33/42
Abstract: The present invention relates to a pharmaceutical composition comprising telmisartan or a pharmaceutically acceptable salt thereof and hydrochlorothiazide or a pharmaceutically acceptable salt thereof as active ingredients, which is a pharmaceutical composition comprising alkali metal phosphate. The present invention has a significant improvement in terms of time and cost by simplifying manufacturing processes, improves patient compliance for taking by minimizing a total capacity of the formulation, provides more stable complex by improving moisture absorption, and satisfies a certain pharmacokinetic parameter. [Reference numerals] (AA) Growth rate(%); (BB) Example 1; (CC) Reference example 1; (DD) Example 5; (EE) Reference example 2; (FF) Time(hr)
Abstract translation: 本发明涉及包含替米沙坦或其药学上可接受的盐和氢氯噻嗪或其药学上可接受的盐作为活性成分的药物组合物，其是包含碱金属磷酸盐的药物组合物。 通过简化制造工艺，本发明在时间和成本方面具有显着的改进，通过使制剂的总容量最小化来提高患者依从性，通过改善吸湿性提供更稳定的复合物，并满足一定的药代动力学参数。 （AA）生长速度（％） （BB）实施例1; （CC）参考实施例1; （DD）实施例5; （EE）参考实施例2; （FF）时间（小时）
-
公开(公告)号：KR1020100069170A
公开(公告)日：2010-06-24
申请号：KR1020080127780
申请日：2008-12-16
Applicant: 삼일제약주식회사
CPC classification number: A61K31/44 , A61K9/2081 , A61K9/5026 , A61K9/5078
Abstract: PURPOSE: A pharmaceutical composition containing lacidipine-containing granule is provided to ensure high elution rate and solubility and to enhance accumulated elution rate. CONSTITUTION: A lacidipine-containing granule is formed by coating lacidipine, surfactant, and polyvinyl pyrrolidone on the surface of water-soluble saccharide particle. The content of surfactant is 5-200 weight parts based on 100 weight parts of lacidipine. The content of polyvinylpyrrolidone is 50-1500 weight parts based on 100 weight parts of lacidipine. The coating is performed by spray-coating on the water-soluble saccharide.
Abstract translation: 目的：提供含有拉西地平颗粒的药物组合物，以确保高洗脱速率和溶解度，并提高积累的洗脱速率。 构成：通过在水溶性糖颗粒表面涂上拉西地平，表面活性剂和聚乙烯吡咯烷酮，形成含有拉西地平的颗粒。 基于100重量份的拉西地平，表面活性剂的含量为5-200重量份。 基于100重量份的拉西地平，聚乙烯吡咯烷酮的含量为50-1500重量份。 涂层通过喷涂在水溶性糖上进行。
-
公开(公告)号：KR101302883B1
公开(公告)日：2013-09-05
申请号：KR1020120079809
申请日：2012-07-23
Applicant: 삼일제약주식회사
IPC: A61K9/20 , A61K31/4184 , A61P7/10
CPC classification number: A61K9/2009 , A61K9/2095 , A61K31/4184 , Y10S514/97
Abstract: PURPOSE: A pharmaceutical composition containing telmisartan as an active ingredient with enhanced stability is provided to save time and costs by a simple manufacturing process and to improve drug compliance by minimizing formulation volume. CONSTITUTION: A pharmaceutical composition contains telmisartan or a pharmaceutically acceptable salt thereof as an active ingredient and also contains an alkali metal phosphate compound as a solubilizing agent. The composition additionally contains a soluble diluent. The alkali metal phosphate compound is Na_3PO_4 or K_3PO_4. A method for manufacturing the pharmaceutical composition comprises the steps of: dissolving a first pharmaceutical ingredient and a phosphate compound in a solvent to prepare a first liquid; dispersing a second pharmaceutical ingredient and a surfactant in a solvent to prepare a second liquid; spraying the first liquid to a pharmaceutically acceptable excipient and preparing granules; spraying the second liquid to the granules and preparing double-coated granules; and filling or tableting the double-coated granules. [Reference numerals] (AA) Elution rate (%); (BB) Example 2; (C1) Comparative example 1; (C2) Comparative example 2; (C3) Comparative example 3; (DD) Time (min)
Abstract translation: 目的：提供含有替米沙坦作为活性成分并具有增强稳定性的药物组合物，以通过简单的制造过程节省时间和成本，并通过最小化制剂体积来改善药物依从性。 构成：药物组合物含有替米沙坦或其药学上可接受的盐作为活性成分，并且还含有作为增溶剂的碱金属磷酸盐化合物。 该组合物另外含有可溶性稀释剂。 碱金属磷酸盐化合物是Na 3 PO 4或K 3 PO 4。 制备药物组合物的方法包括以下步骤：将第一药物成分和磷酸盐化合物溶解在溶剂中以制备第一液体; 将第二药物成分和表面活性剂分散在溶剂中以制备第二液体; 将第一液体喷雾到药学上可接受的赋形剂并制备颗粒; 将第二液体喷雾到颗粒并制备双重包衣颗粒; 并填充或压片双面包衣颗粒。 （AA）洗脱率（％） （BB）实施例2; （C1）比较例1 （C2）比较例2; （C3）比较例3 （DD）时间（分钟）
-
Patent Agency Ranking
公开(公告)号：KR1020120094253A
公开(公告)日：2012-08-24
申请号：KR1020110013635
申请日：2011-02-16
Applicant: 삼일제약주식회사
CPC classification number: A61K38/17 , Y10S514/925
Abstract: PURPOSE: A stability improved sulglycotide, a multi-layer tablet and a manufacturing method thereof are provided to have better damaged stomach protection effects than respectively administrating the sulglycotide and a H2 receptor antagonist. CONSTITUTION: A pharmaceutical composition for treating or preventing gastrointestinal disorder comprises sulglycotide and H2 receptor antagonist as active ingredients. The H2 receptor antagonist is nizatidine, ranitidine, famotidine, cimetidine or lafutidine. The contents of sulglycotide and ranitidine are respectively 50-300mg and 20-300 mg. A multi-layer tablet which includes two or more laminated layers having active materials with different release profiles and a second layer which allows immediate release of H2 acceptor antagonist. The first layer contains 10-300mg of sulglycotide and the second layer contains 10-300mg of H2 acceptor antagonist. A manufacturing method of the multi-layer tablet comprises the following steps: manufacturing the first layer composition which includes the sulglycotide; manufacturing the second layer composition which includes the H2 receptor antagonist; introducing one of the manufactured compositions to the tablet; forming a tablet layer by compressing the introduced tablet layer composition; introducing the other manufactured composition to the tablet press; and forming bilayer tablet by compressing the introduced two compositions.
Abstract translation: 目的：提供稳定性改善的苏格列肽，多层片剂及其制备方法，以比分别施用苏糖苷和H2受体拮抗剂更好地损害胃保护作用。 构成：用于治疗或预防胃肠道疾病的药物组合物包括磺糖苷和H2受体拮抗剂作为活性成分。 H2受体拮抗剂是尼替他啶，雷尼替丁，法莫替丁，西咪替丁或拉夫定。 苏糖苷和雷尼替丁的含量分别为50-300mg和20-300mg。 一种多层片剂，其包含具有不同释放特性的活性物质的两层或更多层压层，以及允许立即释放H 2受体拮抗剂的第二层。 第一层含有10-300mg的苏糖苷，第二层含有10-300mg的H2受体拮抗剂。 多层片剂的制造方法包括以下步骤：制造包含苏糖苷的第一层组合物; 制造包含H 2受体拮抗剂的第二层组合物; 将一种制成的组合物引入片剂; 通过压缩引入的片剂层组合物形成片剂层; 将其他制造的组合物引入压片机; 并通过压缩引入的两种组合物形成双层片剂。
-
公开(公告)号：KR101433428B1
公开(公告)日：2014-08-28
申请号：KR1020110013635
申请日：2011-02-16
Applicant: 삼일제약주식회사
Abstract: 본 발명은 활성성분으로서 설글리코타이드와 라니티딘, 파모티딘, 니자티딘, 시메티딘, 라푸티딘 등으로 구성되는 그룹으로부터 선택되는 하나 이상의 H
2 수용체 길항제를 함유하는 복합 조성물에 관한 것으로, 설글리코타이드를 함유하는 제 1층과, H2 수용체 길항제의 즉각적 방출을 허용하는 제 2층을 포함하는 각기 다른 방출 프로파일을 갖는 두 개 이상의 중첩된 층을 지닌 다층 정제를 제조하여, 제제의 안정성이 개선되고, 활성성분의 체내 흡수를 향상시켜 위궤양 등의 치료율이 향상된 것이다.-
公开(公告)号：KR101466445B1
公开(公告)日：2014-12-01
申请号：KR1020120114062
申请日：2012-10-15
Applicant: 삼일제약주식회사
IPC: A61K31/4184 , A61P9/12 , A61P3/10 , A61P27/06
Abstract: 본발명은텔미사르탄또는이의약제학적으로허용되는염 및하이드로클로로티아지드또는이의약제학적으로허용되는염을유효성분으로포함하는약제학적조성물로서, 알칼리금속인산염을포함하는것을약제학적조성물이다. 본발명은제조공정을간단하게하여시간적및 비용적측면에서크게개선되었을뿐만아니라제제총 용량이최소화되어환자의복약순응도를향상시킬수 있으면서동시에, 흡습성을개선하여보다안정한복합제를제공함과아울러특정한약동학적파라미터를만족한다.
-
公开(公告)号：KR1020110012732A
公开(公告)日：2011-02-09
申请号：KR1020090070578
申请日：2009-07-31
Applicant: 삼일제약주식회사
IPC: A61K9/24 , A61K47/38 , A61K31/4184 , A61P9/12
CPC classification number: A61K9/209 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K9/2063 , A61K31/41 , A61K31/4178 , A61K31/4184 , A61K31/4422 , A61K31/549
Abstract: PURPOSE: A rapidly disintegrating triple layer table is provided to enhance all matrix areas and to improve the elution rate of an active ingredient. CONSTITUTION: A rapidly disintegrating triple layer tablet comprises: a first layer containing an angiotensin II receptor antagonist or calcium channel blocker; a second layer containing silicated microcrystalline cellulose and corsscarmellose sodium, crospovidone, pregelated starch, sodium starch glycolate or low-substituted hydroxy propylcellulose as an disintegrant; and a third layer containing a diuretic.
Abstract translation: 目的：提供快速崩解的三层表，以增强所有基质面积并提高活性成分的洗脱速度。 构成：快速崩解的三层片剂包含：含有血管紧张素II受体拮抗剂或钙通道阻断剂的第一层; 第二层，其中含有硅胶微晶纤维素和西芹糖醇钠，交聚维酮，预胶化淀粉，淀粉羟乙酸钠或低取代羟丙基纤维素作为崩解剂; 和含有利尿剂的第三层。
-
公开(公告)号：KR1020110012729A
公开(公告)日：2011-02-09
申请号：KR1020090070575
申请日：2009-07-31
Applicant: 삼일제약주식회사
IPC: A61K9/16 , A61K31/4184 , A61K9/20 , A61K47/38
CPC classification number: A61K9/1617 , A61K9/1611 , A61K9/1635 , A61K9/1682 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K31/4184
Abstract: PURPOSE: A method for manufacturing telmisartan-containing granules is provided to reduce drying time and to enhance elution rate. CONSTITUTION: A method for manufacturing telmisartan-containing granules comprises: a step of dissolving telmisartan, polyvinyl pyrrolidone and potassium hydroxide in an anhydrous ethanol to obtain a solution; a step of dispersing magnesium oxide in the solution to obtain a dispersion solution; and a step of spray-drying the dispersion solution for granulation. The dispersion solution contains 45-80 weight% of temisartant, 5-15 weight% of potassium hydroxide, 10-50 weight% of polyvinyl pyrrolidone and 0.1-5 weight% of magnesium oxide.
Abstract translation: 目的：提供一种生产替米沙坦颗粒剂的方法，以减少干燥时间和提高洗脱速度。 构成：含替米沙坦的颗粒的制造方法包括：将替米沙坦，聚乙烯吡咯烷酮和氢氧化钾溶解在无水乙醇中以得到溶液的步骤; 将氧化镁分散在溶液中以获得分散液的步骤; 以及喷雾干燥用于造粒的分散液的步骤。 分散溶液含有45-80重量％的暂时性，5-15重量％的氢氧化钾，10-50重量％的聚乙烯吡咯烷酮和0.1-5重量％的氧化镁。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.021 seconds)
